Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial

Amelie Boquoi, MD, Aristoteles Giagounidis, Hartmut Goldschmidt, MD, Michael Heinsch, MD, Mathias J Rummel, MD PhD, Nicolaus Kroeger, David Lopez y Niedenhoff, MD, C. Matthias Wilk, MD, Ingrida Savickaite, MD, Elias K Mai, MD, Carlo Aul, MD, Judith Strapatsas, MD, Ariane Dienst, MD, Mustafa Kondakci, MD, Rainer Haas, MD, Guido Kobbe, Roland Fenk, MD PhD

Blood (2018) 132 (Supplement 1): 2003.

https://doi.org/10.1182/blood-2018-99-110977

Published: 2018

Journal Articles

Changes of the Niche of Erythropoiesis Appear to Contribute to Severe Transfusion-Dependent Anemia in a Significant Proportion of Patients with Myelodysplastic Syndromes

Guntram Buesche, MD, Aristoteles Giagounidis, MD PhD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD Prof., Arnold Ganser, MD, Carlo Aul, MD, Hans Heinrich Kreipe, MD

Blood (2015) 126 (23): 4114.

https://doi.org/10.1182/blood.V126.23.4114.4114

Published: 2015

Journal Articles

Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

Christian T. Dietz, PhD, Alice Charlotte Fabarius, PhD, Michael Lauseker, PhD, Susanne Saussele, Lida Kalmanti, Sébastien Rinaldetti, Claudia Haferlach, MD, Brigitte Schlegelberger, MD PhD, Martine Jotterand, Alois Gratwohl, Axel R. Zander, Professor, Nicolaus Kröger, Dietrich W. Beelen, MD, Jürgen Novotny, Christoph Nerl, Christof Scheid, MD PhD, Karsten Spiekermann, Jiri Mayer, MD, Herbert G. Sayer, Christiane Falge, Donald Bunjes, MD, Hartmut Döhner, Prof. Dr., Arnold Ganser, Peter Brossart, MD, Rainer Schwerdtfeger, Herrad Baumann, Rolf Kuse, Hans Walter Lindemann, MD, Matthias Bormann, Bernd Hertenstein, MD, Gabriela M. Baerlocher, Carlo Aul, MD, Peter Staib, Matthias Edinger, MD, Michael Schatz, Axel A Fauser, Renate Arnold, MD, Dieter K. Hossfeld, MD, Hans-Jochem Kolb, Susanne Schnittger, PhD, Martin C. Müller, MD, Andreas Reiter, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Joerg Hasford, Michele Baccarani, Ruediger Hehlmann, MD

Blood (2015) 126 (23): 1581.

https://doi.org/10.1182/blood.V126.23.1581.1581

Published: 2015

Journal Articles

Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group

Heiko Becker, MD, Stefan Suciu, PhD, Björn Rüter, MD, Uwe Platzbecker, MD, PhD, Aristoteles Giagounidis, MD, Dominik Selleslag, MD, Boris Labar, MD, PhD, Ulrich Germing, MD, Helmut R. Salih, MD, Petra Muus, MD, PhD, Karl-Heinz Pflüger, MD, Anne Hagemeijer, MD, PhD, Hans-Eckart Schaefer, MD, Frédéric Baron, MD, PhD, Arnold Ganser, MD, Carlo Aul, MD, Theo de Witte, MD, Pierre W. Wijermans, MD, Michael Lübbert, MD

Blood (2013) 122 (21): 1452.

https://doi.org/10.1182/blood.V122.21.1452.1452

Published: 2013

Journal Articles

Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.

Guntram Buesche, MD, Aristoteles Giagounidis, MD, Gudrun Göhring, Brigitte Schlegelberger, Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD

Blood (2012) 120 (21): 2826.

https://doi.org/10.1182/blood.V120.21.2826.2826

Published: 2012

Journal Articles

Decitabine (DAC) Vs. Best Supportive Care in Elderly Patients with Intermediate- and High-Risk MDS with or without Monosomal Karyotypes: Results of the EORTC-LG/German MDS-SG Randomized Phase III Trial 06011.

Blood (2012) 120 (21): 2804.

https://doi.org/10.1182/blood.V120.21.2804.2804

Published: 2012

Journal Articles

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

Blood (2011) 118 (21): 2773.

https://doi.org/10.1182/blood.V118.21.2773.2773

Published: 2011

Journal Articles

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

Guntram Buesche, M.D., Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, M.D., Stephanie Dieck, Robert Knight, MD, Carlo Aul, MD, Hans H. Kreipe, MD

Blood (2011) 118 (21): 3819.

https://doi.org/10.1182/blood.V118.21.3819.3819

Published: 2011

Journal Articles

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Blood (2011) 118 (14): 3765–3776.

https://doi.org/10.1182/blood-2011-01-330126

Published: 2011

Includes: Supplemental data

Journal Articles

Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality?

Blood (2010) 116 (21): 4008.

https://doi.org/10.1182/blood.V116.21.4008.4008

Published: 2010

Journal Articles

Prognostic Importance of Duration of MDS Prior to Randomization Between Decitabine (DAC) Vs. Best Supportive Care (BSC) In Elderly IPSS Intermediate-2 and High Risk MDS Patients: Results of the 06011 EORTC-GMDSSG Phase III Trial

Michael Lubbert, Stefan Suciu, Uwe Platzbecker, Aristoteles A.N. Giagounidis, Dominik Selleslag, Boris Labar, Ulrich Germing, Andrea Kuendgen, Helmut R. Salih, Petra Muus, MD, PhD, Björn Rüter, Arnold Ganser, Carlo Aul, Theo de Witte, Pierre W. Wijermans

Blood (2010) 116 (21): 4024.

https://doi.org/10.1182/blood.V116.21.4024.4024

Published: 2010

Journal Articles

Lenalidomide reexposure After Short Interruption In Del(5q) MDS Patients at Relapse of Transfusion Dependence

Robert Marek Radkowski, Sabine Haase, Brigitte Schlegelberger, MD, PhD, Gudrun Goehring, Stefanie Banisch, MD, Michael Heinsch, Carlo Aul, Aristoteles Giagounidis

Blood (2010) 116 (21): 2923.

https://doi.org/10.1182/blood.V116.21.2923.2923

Published: 2010

Journal Articles

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy

Georg Russwurm, Michael Heinsch, Robert Radkowski, Rainer Erlemann, Carlo Aul, Sabine Haase, Aristoteles Giagounidis

Blood (2010) 116 (14): 2617–2618.

https://doi.org/10.1182/blood-2010-04-279786

Published: 2010

Journal Articles

Incidence and Prevalence of Patients with Myelodysplastic Syndromes (MDS) in Düsseldorf 1996-2005.

Judith Neukirchen, W. Marieke Schoonen, Carlo Aul, Rainer Haas, Norbert Gattermann, MD, PhD, Ulrich Germing

Blood (2009) 114 (22): 1774.

https://doi.org/10.1182/blood.V114.22.1774.1774

Published: 2009

Journal Articles

Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression.

Gudrun Göhring, MD, Aristoteles Giagounidis, Guntram Büsche, MD, Hans Kreipe, MD, Martin Zimmermann, PhD, Eva Hellstrom-Lindberg, MD, PhD, Carlo Aul, Brigitte Schlegelberger, M.D.

Blood (2009) 114 (22): 3818.

https://doi.org/10.1182/blood.V114.22.3818.3818

Published: 2009

Journal Articles

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

Guntram Buesche, MD, Stephanie Dieck, Aristoteles Giagounidis, MD, Gudrun Göhring, MD, Brigitte Schlegelberger, MD, Robert Knight, MD, Carlo Aul, MD, Hans Kreipe, MD

Blood (2009) 114 (22): 3800.

https://doi.org/10.1182/blood.V114.22.3800.3800

Published: 2009

Journal Articles

Discontinuation of Lenalidomide in Patients with Transfusion-Dependent Low- and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5q): Sustained Remissions, but Not Cure.

Aristoteles Giagounidis, Gudrun Göhring, MD, Sabine Haase, Carlo Aul, Brigitte Schlegelberger, M.D., Andrea Kuendgen, Regina Herbst, MD, Gerhard Ehninger, Uwe Platzbecker

Blood (2009) 114 (22): 3807.

https://doi.org/10.1182/blood.V114.22.3807.3807

Published: 2009

Journal Articles

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

Pierre Fenaux, Aristotle Giagounidis, Dominik Selleslag, MD, Odile Beyne-Rauzy, MD, PhD, Ghulam J Mufti, MBBS, DM, FRCP, FRCPath, Moshe Mittelman, MD, Petra Muus, MD, PhD, Peter te Boekhorst, MD, PhD, Guillermo Sanz, MD, PhD, Consuelo del Cañizo, Agnes Guerci-Bresler, Brigitte Schlegelberger, M.D., Carlo Aul, Hans Kreipe, MD, Gudrun Goehring, Robert Knight, MD, John Francis, Tommy Fu, Eva Hellstrom-Lindberg, MD, PhD

Blood (2009) 114 (22): 944.

https://doi.org/10.1182/blood.V114.22.944.944

Published: 2009

Journal Articles

Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).

Blood (2009) 114 (22): 945.

https://doi.org/10.1182/blood.V114.22.945.945

Published: 2009

Journal Articles

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

Blood (2009) 114 (22): 485.

https://doi.org/10.1182/blood.V114.22.485.485

Published: 2009

NARROW

Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial

Changes of the Niche of Erythropoiesis Appear to Contribute to Severe Transfusion-Dependent Anemia in a Significant Proportion of Patients with Myelodysplastic Syndromes

Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group

Reduction of Erythropoiesis in MDS with 5q Deletion Is Associated with Aberrant SPARC and TNF-Alpha Gene Expression and Predicts the Efficacy of Lenalidomide Therapy.

Decitabine (DAC) Vs. Best Supportive Care in Elderly Patients with Intermediate- and High-Risk MDS with or without Monosomal Karyotypes: Results of the EORTC-LG/German MDS-SG Randomized Phase III Trial 06011.

Outcome of Myelodysplastic Syndrome Treated with Intensive Chemotherapy within the AMLCG99 Trial

Prognosis of Low- or Intermediate-1-Risk MDS with Del(5q) Chromosome Abnormality During Lenalidomide Therapy Depends on the Capacity of the Neoplastic Stem Cell to Differentiate Into Maturing Erythroid Committed Stem Cells,

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Loss of the Y Chromosome in MDS - Age-Related Phenomenon or Clonal Abnormality?

Prognostic Importance of Duration of MDS Prior to Randomization Between Decitabine (DAC) Vs. Best Supportive Care (BSC) In Elderly IPSS Intermediate-2 and High Risk MDS Patients: Results of the 06011 EORTC-GMDSSG Phase III Trial

Lenalidomide reexposure After Short Interruption In Del(5q) MDS Patients at Relapse of Transfusion Dependence

Dasatinib induces complete remission in a patient with primary cerebral involvement of B-cell chronic lymphocytic leukemia failing chemotherapy

Incidence and Prevalence of Patients with Myelodysplastic Syndromes (MDS) in Düsseldorf 1996-2005.

Patients with Del(5q) MDS Who Fail to Achieve Erythroid or Cytogenetic Remission After Treatment with Lenalidomide Have An Increased Risk for Clonal Evolution and AML Progression.

Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality.

Discontinuation of Lenalidomide in Patients with Transfusion-Dependent Low- and Intermediate-1 Risk Myelodysplastic Syndromes with Del(5q): Sustained Remissions, but Not Cure.

RBC Transfusion Independence and Safety Profile of Lenalidomide 5 or 10 mg in Pts with Low- or Int-1-Risk MDS with Del5q: Results From a Randomized Phase III Trial (MDS-004).

Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only